Dendritic Cell-Based Vaccine for the Treatment of Malignant Glioma: A Systematic Review

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Investigation

• Publication date

  2014-10-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/07357907.2014.958234PMID 25259676
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fusions between dendritic cells and whole tumor cells as anticancer vaccines

  2013cited by this paper
• Immune-Checkpoint Blockade and Active Immunotherapy for Glioma

  2013cited by this paper
• Adoptive Cell Therapies for Glioblastoma

  2013cited by this paper
• Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

  2013cited by this paper
• Comparison of Glioma-associated Antigen Peptide-loaded Versus Autologous Tumor Lysate-loaded Dendritic Cell Vaccination in Malignant Glioma Patients

  2013cited by this paper
• Current status of immunotherapy and gene therapy for high-grade gliomas.

  2013cited by this paper
• Immunotherapy for glioma: promises and challenges.

  2012cited by this paper
• Cancer immunotherapy

  2012cited by this paper
• Clinical trials with immunotherapy for high-grade glioma.

  2012cited by this paper
• Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

  2012cited by this paper
• Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?

  2012cited by this paper
• Immunotherapy for the Treatment of Glioblastoma

  2012cited by this paper
• Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?

  2012cited by this paper
• Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial.

  2012influential reference
• Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

  2011cited by this paper
• Commentary on "Sipuleucel-T immunotherapy for castration-resistant prostate cancer". Kantoff PW, Higano CS, Shore ND, Berger

  2011cited by this paper
• A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma.

  2011influential reference
• Clinical Application of a Dendritic Cell Vaccine Raised Against Heat-Shocked Glioblastoma

  2011influential reference
• Cancer immunotherapy.

  2011cited by this paper
• Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy

  2010cited by this paper
• Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

  2010cited by this paper
• Immune therapy for cancer.

  2009cited by this paper
• CONVECTION‐ENHANCED DELIVERY OF CINTREDEKIN BESUDOTOX (INTERLEUKIN‐13‐PE38QQR) FOLLOWED BY RADIATION THERAPY WITH AND WITHOUT TEMOZOLOMIDE IN NEWLY DIAGNOSED MALIGNANT GLIOMAS: PHASE 1 STUDY OF FINAL SAFETY RESULTS

  2007cited by this paper
• WHO classification of tumours of the central nervous system

  2007cited by this paper
• The 2007 WHO Classification of Tumours of the Central Nervous System

  2007cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.

  2005influential reference
• Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells

  2005cited by this paper
• Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment

  2005cited by this paper
• Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma.

  2005cited by this paper
• Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study.

  2004cited by this paper
• Systematic Comparison of Dendritic Cell-based Immunotherapeutic Strategies for Malignant Gliomas: In Vitro Induction of Cytolytic and Natural Killer-like T Cells

  2004cited by this paper
• Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma

  2004cited by this paper
• Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes.

  2000cited by this paper
• Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991.

  1998cited by this paper
• Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

  1996cited by this paper
• Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.

  1992cited by this paper
• Iodine-125-labeled anti-epidermal growth factor receptor-425 in the treatment of glioblastoma multiforme. A pilot study.

  1990cited by this paper
• Preliminary trial of specific targeting therapy against malignant glioma.

  1990cited by this paper
• Iodine-125-labeled anti-epidermal growth factor receptor-425 in the treatment of glioblastoma multiforme. A pilot study.

  1989cited by this paper
• Immune therapy of cancer.

  1988cited by this paper
• Clinical Medicine Insights: Oncology O R I G I N a L R E S E a R C H Influence of Immunotherapy with Autologous Dendritic Cells on Innate and Adaptive Immune Response in Cancer Discipline of Gynaecology and Obstetrics

  year unknowncited by this paper

• Brain Delivery of Biomimetic Phosphorus Dendrimer/Antibody Nanocomplexes for Enhanced Glioma Immunotherapy via Immune Modulation of T Cells and Natural Killer Cells.

  2024cites this paper
• Challenges and advances in glioblastoma targeted therapy: the promise of drug repurposing and biomarker exploration

  2024cites this paper
• From promise to progress: the dynamic landscape of glioblastoma immunotherapy.

  2024cites this paper
• Dendritic cell vaccine for glioblastoma: an updated meta-analysis and trial sequential analysis

  2024cites this paper
• Efficacy and Safety of Vaccines After Conventional Treatments for Survival of Gliomas: A Systematic Review and Meta-Analysis

  2024cites this paper
• Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients.

  2024cites this paper
• Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?

  2023cites this paper
• Nanobiotechnology-based treatment strategies for malignant relapsed glioma.

  2023cites this paper
• Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review

  2023cites this paper
• Glioma diagnosis and therapy: Current challenges and nanomaterial-based solutions.

  2022cites this paper
• Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

  2022cites this paper
• The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.

  2021cites this paper
• Pharmacological strategies for improving the prognosis of glioblastoma

  2021cites this paper
• Dendritic Cell–Targeted Therapies to Treat Neurological Disorders

  2021cites this paper
• Efficacy and safety of dendritic cell vaccines for patients with glioblastoma: A meta-analysis of randomized controlled trials.

  2020cites this paper
• CURRENT TRENDS IN MEDICAL AND CLINICAL CASE REPORTS

  2020cites this paper
• Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged

  2020cites this paper
• Assessment of the efficacy of passive cellular immunotherapy for glioma patients

  2020cites this paper
• Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy

  2019cites this paper
• Technical Challenges in the Manufacture of Dendritic Cell Cancer Therapies

  2019cites this paper
• Efficacy and Safety of Immunotherapy and Standard of Care in High-Grade Gliomas: A Systematic Review and Meta-analysis

  2019cites this paper
• Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?

  2018cites this paper
• The Induction of Immunogenic Cell Death ( ICD ) During Maintenance Chemotherapy and Subsequent Multimodal Immunotherapy for Glioblastoma ( GBM )

  2018cites this paper
• A Dendritic Cell-Targeted Adenoviral Vector Facilitates Adaptive Immune Response Against Human Glioma Antigen (CMV-IE) and Prolongs Survival in a Human Glioma Tumor Model

  2018cites this paper
• Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme

  2018cites this paper
• Evolutionary basis of a new approach for the treatment of malignant brain tumors: from mice to humans

  2018cites this paper
• Efficacy and safety analysis on dendritic cell-based vaccine-treated high-grade glioma patients: a systematic review and meta-analysis

  2018cites this paper
• Dendritic Cell Therapy for Brain Tumors

  2017cites this paper
• Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

  2017cites this paper
• The development of dendritic cell vaccine-based immunotherapies for glioblastoma

  2017cites this paper
• Effect and molecular mechanism of mTOR inhibitor rapamycin on temozolomide-induced autophagic death of U251 glioma cells.

  2017cites this paper
• [Immunotherapy in brain tumors].

  2017cites this paper
• Immunothérapie des tumeurs cérébrales

  2017cites this paper
• Dendritic cells in brain diseases.

  2016cites this paper
• Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells.

  2016cites this paper
• Towards understanding of Human Cytomegalovirus in Glioblastoma

  2016cites this paper
• Expression of CDC5L is associated with tumor progression in gliomas

  2016cites this paper
• Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results

  2016cites this paper
• Advances in immunotherapy for the treatment of glioblastoma

  2016cites this paper
• The immunosuppressive network in patients with glioma; focus on the role of myeloid derived suppressor cells

  2016cites this paper
• In situ dendritic cell vaccination for the treatment of glioma and literature review

  2016cites this paper
• Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.

  2016cites this paper
• Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.

  2015cites this paper
• Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme

  2015cites this paper
• Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy

  2015cites this paper
• Alkannin inhibits growth and invasion of glioma cells C6 through IQGAP/mTOR signal pathway.

  2015cites this paper
• Dendritic cell immunotherapy

  2013cites this paper
• Glioblastoma Immunotherapy Combinations Offer Hope in Glioblastoma

  year unknowncites this paper